Latest Industry Insights

In this interview, Dr. Christian Schafmeister discusses the structural advantages of Spiroligomer molecules, their ability to disrupt protein–protein interactions and their potential applications in cancer therapy and beyond.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

UK Biocentre is adopting Azenta’s BioArc™ Ultra™, an automated -80°C storage system, to enhance biobanking efficiency and sustainability. With high-density storage and precise temperature control, it safeguards valuable samples.

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.

Vivek Vishnudas discusses the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.

Cancer Research Horizons and Diamond Light Source aim to strengthen their partnership, combining their expertise and resources to bring new cancer treatments to patients.

In this interview, Professor Ola Söderberg explores the development of MolBoolean, its innovative methodology and the advantages it offers over existing techniques.

Technology Networks spoke with Dr. Mohamed Alameri to explore how population-wide genome initiatives are addressing gaps in genomic data representation and advancing precision medicine in areas such as rare diseases and cancer.

Technology Networks spoke with Nicola Alderson, COO at Anthony Nolan, to discuss some of the current stem cell supply challenges and learn more about how donor registries can help overcome stem cell supply chain issues.

In this interview, Technology Networks spoke with Dr. Roy Maute, co-founder and CEO of Pheast Therapeutics, to learn about macrophage checkpoint therapies and the potential they hold for cancer treatment.